Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Alkaptonuria

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Alkaptonuria

Alaa F. Sharabi et al.
Free Books & Documents

Excerpt

Alkaptonuria is one of a rare autosomal recessive genetic disorder, which results from the deficiency of homogentisate 1,2 dioxygenase (HGD). HGD gene is expressed in the liver, kidney, prostate, small intestine, and colon. This enzyme plays a role in the metabolism of tyrosine that converts homogentisic acid (HGA) into malate and acetoacetate. In the absence of HGD, homogentisic acid produced in excess by the liver oxidizes into ochronotic pigment polymer. Accumulation of this pigment in various tissues leads to systemic disease. This process is called ochronosis.

Alkaptonuria was amongst the first genetic disorders in humans that found to follow the principles of Mendelian recessive inheritance. Historically, in 1908 it was used by Archibald Garrod in his Croonian lectures to illustrate the principles behind "inborn errors of metabolism." However, the Egyptian mummy Harwa believed to be the first clinical case of Alkaptonuria dating back as far as 1500 BC. The term alkaptonuria originated from the Arabic word "alkali." Also, Boedeker created the name in 1859 after he noticed unusual decreasing properties in patient urine. In 1866 ochronosis was discovered by Virchow, who noticed under microscopy when HGA pigment appeared to be a pale brownish yellow color (ochre-like).

PubMed Disclaimer

Conflict of interest statement

Disclosure: Alaa Sharabi declares no relevant financial relationships with ineligible companies.

Disclosure: Raghavendra Goudar declares no relevant financial relationships with ineligible companies.

Similar articles

References

    1. Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria (invited review; best practice article). J Clin Pathol. 2013 May;66(5):367-73. - PubMed
    1. Mistry JB, Bukhari M, Taylor AM. Alkaptonuria. Rare Dis. 2013;1:e27475. - PMC - PubMed
    1. Fisher AA, Davis MW. Alkaptonuric ochronosis with aortic valve and joint replacements and femoral fracture: a case report and literature review. Clin Med Res. 2004 Nov;2(4):209-15. - PMC - PubMed
    1. Gottschalk BH, Blankenstein J, Guo L. Ochronosis of Mitral Valve and Coronary Arteries. Ann Thorac Surg. 2018 Jul;106(1):e19-e20. - PubMed
    1. Langford B, Besford M, Hall A, Eddowes L, Timmis O, Gallagher JA, Ranganath L. Alkaptonuria Severity Score Index Revisited: Analysing the AKUSSI and Its Subcomponent Features. JIMD Rep. 2018;41:53-62. - PMC - PubMed

Publication types

LinkOut - more resources